跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 888 条关于
“TfR1 CapX”
全部
888
临床试验
724
药物
85
机构
8
资讯
71
7个月前
Apertura Gene Therapy Launches Open Aperture Program to Democratize Access to CNS-Targeting AAV Capsid
去年
Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners for CNS Treatments
去年
Apertura Gene Therapy Partners with Rett Syndrome Research Trust to Advance Blood-Brain Barrier-Crossing Gene Therapy Platform
2个月前
Engineered Bispecific Antibody Shuttles Unlock Dual-Receptor Pathway Across the Blood–Brain Barrier
去年
Avidity Biosciences Secures $345M Following Promising Duchenne Muscular Dystrophy Trial Results
上个月
Korsana Biosciences goes public with USD 380m raise as Alzheimer's antibody KRSA-028 heads toward Phase I
去年
Dyne Therapeutics Strengthens Leadership Team with Key Scientific and Business Appointments
去年
NanoNewron Secures $2.5M NIH Grant to Advance Blood-Brain Barrier Crossing TNF-Alpha Inhibitor for Alzheimer's Disease
去年
Avidity Biosciences Advances Delpacibart Braxlosiran for FSHD with Biomarker Cohort
2年前
Avidity's Delpacibart Etedesiran Granted FDA Breakthrough Therapy Designation for Myotonic Dystrophy Type 1
第 1 页,共 8 页
上一页
下一页